

Company name: **ImmuneWalk Therapeutics**

Website: <https://www.immunewalk.com>

CEO name: **Prof. Dror Harats**

CATEGORY: **Biotech/Pharma**

Select up to two SESSIONS per abstract from the list below *
(Delete sessions you are not selecting)

- Hospital at home: universities 'and hospitals' innovations
- Israeli medical contribution to breakthrough science and technology

o **Executive Summary / Investment Rational** Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

New Biology Translated to Innovative Therapy: ImmuneWalk Therapeutics is an I&I company with first-in-class mAb for highly prevalent and rare inflammatory indications, addressing a multi-billion \$ market. Over \$20M have been invested in the program to date. First-in-man clinical trial of lead candidate IW-601 is expected to start in 2Q2024.

o **Core Technology** What is the technology, its uniqueness, and its value proposition?

There is no treatment specifically targeting monocytes, key immune cells controlling the inflammatory response. We developed a differentiated technology, based on new biology – targeting a novel adhesion checkpoint (the MOSPD2 protein) that blocks the ability of monocytes to reach inflamed tissues.

o **Product Profile/Pipeline** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non-Alcoholic Steatohepatitis (NASH), in addition to proof-of-concept from patients' cells, we are advancing IW-601 to Ph1 clinical trial with multiple catalysts expected in 2025-2026.

o **Business Strategy** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

IW-601 has potential to be broadly applicable across both prevalent & rare inflammatory indications. Our current focus is on providing human proof-of-concept and safety. Our Ph1 trial is expected to provide valuable PK, PD, biomarker data.

o **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans**

Beyond advancing IW-601 through clinical trials for I&I indications, our program has additional potential in oncology, as MOSPD2 is also implicated in cancer metastasis.